Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

Video

In Partnership With:

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha (FRα) as a biomarker for mirvetuximab soravtansine response in the treatment of patients with ovarian cancer.

FRα is starting to pan out as a biomarker for mirvetuximab soravtansine, O’Malley says. In the phase Ib FORWARD II study presented at the 2018 ASCO Annual Meeting, researchers looked at patients with platinum-resistant ovarian cancer and divided them into subgroups based on FRα expression. Low expressers were defined as 25% to 50%, moderate expressers were 50% to 75%, and high expressers were >75%. As more experience has been gained with the use of mirvetuximab soravtansine in these patient populations, gynecologic oncologists are starting to see that the medium- and high-expressers of FRα are doing better in the progression-free and overall survival data.

O’Malley adds that while they are now focusing on the medium and high expressers, marked responses are still seen in the low expressers.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD